Suppr超能文献

新辅助治疗局部晚期乳腺癌病例中影响病理完全缓解的因素:一项综合文献综述

Factors Affecting Pathological Complete Response in Locally Advanced Breast Cancer Cases Receiving Neoadjuvant Therapy: A Comprehensive Literature Review.

作者信息

Alamoodi Munaser

机构信息

Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

出版信息

Eur J Breast Health. 2023 Dec 27;20(1):8-14. doi: 10.4274/ejbh.galenos.2023.2023-11-2. eCollection 2024 Jan.

Abstract

Determining pathological complete response (pCR) could be an important step in planning individual treatment, hence improving the prognosis in terms of survival. Achieving breast pCR not only improves survival but is also linked to a disease-free axilla, therefore increasing the likelihood of avoiding axillary surgery safely. The current trend in de-escalating axillary management surgically or in applying radiotherapy to the axilla is dependent primarily on breast cancer (BC) patients achieving pCR. Studies have demonstrated that certain characteristics can predict pCR, even though it is still difficult to identify these elements. A review of the literature was carried out to determine these factors and their clinical applications. A search was carried out in the MEDLINE database using PubMed, Google Scholar, and EMBASE. This yielded 1368 studies, of which 60 satisfied the criteria. The studies were categorized according to the subject they dealt with. These parameters included age, race, subtypes, clinicopathological, immunological, imaging, obesity, Ki-67 status, vitamin D, and genetics. These factors, in combination, can be used for specific subtypes to individualize treatment and monitor response to therapy. The predictors of pCR are diverse and should be utilized to personalize patient treatment, ultimately inducing the best outcomes. These determinants can also be employed for monitoring responses to neoadjuvant therapy, thereby adjusting treatment. The development of standardized markers for the diversity of BC subtypes still needs additional future research. These factors must be applied in concert in order to provide optimal results.

摘要

确定病理完全缓解(pCR)可能是规划个体化治疗的重要一步,从而改善生存预后。实现乳腺pCR不仅能提高生存率,还与腋窝无病状态相关,因此增加了安全避免腋窝手术的可能性。目前在手术上降低腋窝处理强度或对腋窝应用放疗的趋势主要取决于乳腺癌(BC)患者是否达到pCR。研究表明,某些特征可以预测pCR,尽管识别这些因素仍然困难。为了确定这些因素及其临床应用,我们进行了文献综述。我们使用PubMed、谷歌学术和EMBASE在MEDLINE数据库中进行了检索。这产生了1368项研究,其中60项符合标准。这些研究根据其涉及的主题进行了分类。这些参数包括年龄、种族、亚型、临床病理、免疫、影像、肥胖、Ki-67状态、维生素D和遗传学。这些因素结合起来,可用于特定亚型以实现个体化治疗并监测治疗反应。pCR的预测因素多种多样,应加以利用以实现患者治疗的个性化,最终诱导出最佳结果。这些决定因素还可用于监测新辅助治疗的反应,从而调整治疗。针对BC亚型多样性的标准化标志物的开发仍需要未来进一步研究。这些因素必须协同应用才能提供最佳结果。

相似文献

1
Factors Affecting Pathological Complete Response in Locally Advanced Breast Cancer Cases Receiving Neoadjuvant Therapy: A Comprehensive Literature Review.
Eur J Breast Health. 2023 Dec 27;20(1):8-14. doi: 10.4274/ejbh.galenos.2023.2023-11-2. eCollection 2024 Jan.
3
Overview of resistance to systemic therapy in patients with breast cancer.
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
5
9
Factors Predicting Response in Breast Cancer Receiving Neoadjuvant Therapy and the Role of Ki67 Labeling Index.
J Coll Physicians Surg Pak. 2023 Aug;33(8):872-878. doi: 10.29271/jcpsp.2023.08.872.
10
[Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].
Rev Esp Med Nucl Imagen Mol. 2015 Jul-Aug;34(4):230-5. doi: 10.1016/j.remn.2015.01.005. Epub 2015 Mar 3.

引用本文的文献

1
Predictors of High-Burden Residual Axillary Disease After Neoadjuvant Therapy in Breast Cancer.
Cancers (Basel). 2025 May 8;17(10):1596. doi: 10.3390/cancers17101596.
2
Dismal pathological response to neoadjuvant chemotherapy in stage III breast cancer patients in Tanzania: A retrospective review.
PLoS One. 2025 Apr 23;20(4):e0321187. doi: 10.1371/journal.pone.0321187. eCollection 2025.
3
Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.
Ther Adv Med Oncol. 2024 Dec 23;16:17588359241309169. doi: 10.1177/17588359241309169. eCollection 2024.
5
Prognostic Evaluation of Piezo2 Channels in Mammary Gland Carcinoma.
Cancers (Basel). 2024 Jun 29;16(13):2413. doi: 10.3390/cancers16132413.

本文引用的文献

1
Factors Predicting Response in Breast Cancer Receiving Neoadjuvant Therapy and the Role of Ki67 Labeling Index.
J Coll Physicians Surg Pak. 2023 Aug;33(8):872-878. doi: 10.29271/jcpsp.2023.08.872.
3
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.
Breast Cancer Res Treat. 2023 Jul;200(1):75-83. doi: 10.1007/s10549-023-06943-x. Epub 2023 Apr 29.
6
New insights into breast microcalcification for poor prognosis: NACT cohort and bone metastasis evaluation cohort.
J Cancer Res Clin Oncol. 2023 Aug;149(10):7285-7297. doi: 10.1007/s00432-023-04668-4. Epub 2023 Mar 14.
7
The Predictive Importance of Body Mass Index on Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer.
Breast Care (Basel). 2023 Feb;18(1):42-48. doi: 10.1159/000526732. Epub 2022 Sep 14.
9
Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world.
Front Mol Biosci. 2022 Sep 26;9:996434. doi: 10.3389/fmolb.2022.996434. eCollection 2022.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验